Abate, T. 2001a. ‘Genentech can widen drug's use’, San Francisco Chronicle, 15 May, p. B1Google Scholar

Abate, T. 2001b. ‘Researchers ready to move to next genome discoveries; drug developers to see new tools at Trade Show’, San Francisco Chronicle, 5 March, p. C1Google Scholar

Abraham, J. 1995. Science, Politics and the Pharmaceutical Industry: Controversy and Bias in Drug Regulation. London: University College London/St Martins Press

Aerssens, J. 2002. ‘Pharmacogenomic approaches in Alzheimer's disease drug development’, Drug Development Research 56: 67–73CrossRefGoogle Scholar

AGS Ethics Committee 2001. ‘Genetic testing for late-onset Alzheimer's disease’, Journal of the American Geriatric Society 49: 225–6CrossRef

Akhtar, S. 2002. ‘Pharmacogenomics: are pharmacists ready for genotyped prescribing?’, Pharmaceutical Journal 268: 296–9Google Scholar

Almkvist, O, , Jelic, V., Amberla, K., Hellstrom-Lindhal, E., Meuling, L. and Nordberg, A. 2001. ‘Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients’, Dementia and Geriatric Cognitive Disorders 12(1): 22–32CrossRefGoogle Scholar

Altman, L. K. 2000. ‘Reading the book of life: the doctor's world; genomic chief has high hopes, and great fears, for genetic testing’, New York Times, 27 June, section F, p. 6Google Scholar

Altman, R. 1996. Waking Up/Fighting Back: The Politics of Breast Cancer. Boston: Little, Brown

Álvarez, X. A., Mouzo, R., Pichel, V., Perez, P., Laredo, M., Fernandez-Novoa, L., Corzo, L., Zas, R., Alcaraz, M., Secades, J. J., Lozano, R. and Cacabelos, R. 1999. ‘Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion’, Methods and findings in Experimental and Clinical Pharmacology 21(9): 633–44Google ScholarPubMed

Anderson, D. C., Gomez-Mancilla, B., Spear, B. B., Barnes, D. M., Cheeseman, K., Shaw, P. M., Friedman, J., McCarthy, A., Brazell, C., Ray, S. C., McHale, D., Hashimoto, L., Sandbrink, R., Watson, M. L., Salerno, R. A., Cohen, N. and Lister, C. E. on behalf of the Pharmacogenetics Working Group 2002. ‘Elements of informed consent for pharmacogenetic research; perspective of the Pharmacogenetics Working Group’, Pharmacogenomics Journal 2(5): 284–92CrossRefGoogle ScholarPubMed

Anderson, W. H., Fitzgerald, C. G. and Manasco, P. K. 1999. ‘Current and future applications of pharmacogenomics’, New Horizons: Science and Practice of Acute Medicine 7(2): 262–9Google Scholar

Anglin, M. K. 1997. ‘Working from the inside out: implications of breast cancer activism for biomedical policies and practices’, Social Science and Medicine 44(9): 1403–15CrossRefGoogle ScholarPubMed

,Anon. 1998. ‘Editorial: pharmacogenomics at work’, Nature Biotechnology 16(10): 885CrossRefGoogle Scholar

Anspach, R. 1993. Deciding who Lives: Fateful Choices in the Intensive-Care Nursery. Berkeley: University of California Press

Ashcroft, R. 1999. ‘Equipoise, knowledge and ethics in clinical research and practice’, Bioethics 13(3–4): 314–26CrossRefGoogle ScholarPubMed

Ashmore, M., Mulkay, M. and Pinch, T. 1989. Health and Efficiency: A Sociology of Health Economics. Milton Keynes: Open University Press

Bailey, D. S., Bondar, A. and Furness, L. M. 1998. ‘Pharmacogenomics – it's not just pharmacogenetics’, Current Opinion in Biotechnology 9: 595–601CrossRefGoogle Scholar

Barry, A. 2001. Political Machines: Governing a Technological Society. London and New York: Athlone

Barton, G. 2000. Genetic Services in the NHS: An Institute of Healthcare Management Discussion Paper. London: HMSO

Baselga, J. 2001. ‘Clinical trials of Herceptin® (trastuzumab)’, European Journal of Cancer 37: S18–S24CrossRefGoogle Scholar

Bast, R. C., Ravdin, P., Hayes, D. F., Bates, S., Fritsche, H., Jessup, J. M., Kemeny, N., Locker, G. Y., Mennel, R. G. and Somerfield, M. R. 2001. ‘2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology’, Journal of Clinical Oncology 19(6): 1865–78CrossRefGoogle ScholarPubMed

Batt, S. 1994. Patient no More: The Politics of Breast Cancer. London: Scarlet

Batt, S. 2000. ‘The new genetic therapies: the case of herceptin for breast cancer’, in The Gender of Genetic Futures: The Canadian Biotechnology Strategy. Women and Health Proceedings of the National Strategic Workshop, NNEWH Working Paper Series. Toronto: York University Press, pp. 9–17

Bazell, R. 1998. Her2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer. New York: Random House

Beauchamp, T. L. and Childress, J. F. 1993. Principles of Biomedical Ethics. 4th edn. Oxford: Oxford University Press

Bell, R. A., Wilkes, M. S. and Kravitz, R. L. 1999. ‘Advertisement-induced prescription drug requests: patient's anticipated reactions to a physician who refuses’, Journal of Family Practice 48(6): 446–52Google Scholar

Benbassat, J., Pilpel, D. and Tidhar, M. 1998. ‘Patient's preferences for participation in clinical decision making: a review of published surveys’, Behavioral Medicine 24(2): 81–8CrossRefGoogle ScholarPubMed

Berg, J. W., Appelbaum, P. S., Lidz, C. W. and Parker, L. S. 2001. Informed Consent: Legal Theory and Clinical Practice. 2nd edn. Oxford: Oxford University Press

Bijker, W., Hughes, T. and Pinch, T. (eds.) 1987. The Social Construction of Technological Systems. Cambridge, MA: MIT Press

Bijker, W. E. and Law, J. (eds.) 1992. Shaping Technology-Building Society: Studies in Sociotechnical Change. Cambridge, MA: MIT Press

Binstock, R. H. and Murray, T. H. 1998. ‘Genetics and long-term-care insurance: ethical and policy issues’, in S. G. Post and P. J. Whitehouse (eds.), Genetic Testing for Alzheimer's Disease: Ethical and Clinical Issues. Baltimore: Johns Hopkins University Press, pp. 155–76

Birch, S. and Gafni, A. 2002. ‘On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales’, Health Economics 11: 185–91CrossRefGoogle ScholarPubMed

Bird, T. 1995a. ‘Apolipoprotein E genotyping in diagnosis of Alzheimer's disease: a cautionary view’, Annals of Neurology 38(1): 2–3CrossRefGoogle Scholar

Bird, T. 1995b. ‘Reply’, Annals of Neurology 38(6): 967CrossRefGoogle Scholar

Birner, P. 2002. ‘Is fluorescence in situ hybridization really superior to Hercept Test?’ Journal of Clinical Oncology 20(23): 4607CrossRefGoogle Scholar

Bogdanovic, S. and Langlands, B. 1999. Pharmacogenomics Players. London: Financial Times

Bonnor, J. 1998. ‘Designer drugs’, Guardian, 5 February, p. 14Google Scholar

Booth, B, ., Glassman, R. and Ma, P. 2003. ‘Oncology's trials’, Nature Reviews Drug Discovery 2(8): 609–10CrossRefGoogle Scholar

Borroni, B., Colciaghi, F., Pastorino, L., Archetti, S., Corsini, P., Cattabeni, F., Di Luca, M. and Padovani, A. 2002. ‘ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model’, European Neuropsychopharmacology 12: 195–200CrossRefGoogle ScholarPubMed

Boseley, S. 2003. ‘Cancer fund urged to end postcode lottery’, Guardian, 29 October, p. 11Google Scholar

Bosk, C. L. 1992. All God's Mistakes: Genetic Counselling in a Pediatric Hospital. Chicago: University of Chicago Press

Bosk, C. L. 2002. ‘Obtaining voluntary consent for research in desperately ill patients’, Medical Care 40(9): V64–8CrossRefGoogle ScholarPubMed

Bowe, C. and Pilling, D. 2001. ‘Abbott labs links with Millennium’, Financial Times, 13 March, p. 17Google Scholar

Bracco, L. 2002. ‘Pharmacogenomics and personalised medicine’, Pharmacogenomics 3(2): 166–71CrossRefGoogle ScholarPubMed

Branca, M. 2002. ‘Gambling on pharmacogenomics: a Q&A with Klaus Lindpaintner’, Bio IT World, 9 October, http://www_bio-itworld.com/archive/100902/path_sidebar_1303.htmGoogle Scholar

Brill-Edwards, M. 1999. ‘Canada's Health Protection Branch: whose health, what protection?’, in M. L. Barer, K. M. McGrail, K. Cardiff, L. Wood and C. J. Green (eds.), Tales from the Other Drug Wars: Papers from the 12th Annual Health Policy Conference (held in Vancouver, BC, 26 November 1999). Vancouver: University of British Columbia, Centre for Health Services and Policy Research, http://www.chspr.ubc.ca/misc/drugwars2.pdf

Brodaty, H., Conneally, M., Gauthier, S., Jennings, C., Lennox, A., Lovestone, S., Koczyn, A., Mangone, C., Rossor, M. and Whitehouse, P. 1995. ‘Consensus statement on predictive testing for Alzheimer Disease’, Alzheimer Disease and Associated Disorders 9(4): 182–7Google ScholarPubMed

Brower, V. 1997. ‘Allen Roses: rebel with a cause’, Nature Biotechnology 15: 1310CrossRefGoogle Scholar

Brown, H. 2003. ‘Does hope match the hype for targeted drugs?’, Lancet Oncology 4(8): 452CrossRefGoogle ScholarPubMed

Brown, L. 1998. ‘The evolution of managed care in the US’, Pharmacoeconomics 14(1): 37–43CrossRefGoogle ScholarPubMed

Brown, N., Rappert, B. and Webster, A. (eds.) 2000. Contested Futures: A Sociology of Prospective Science and Technology. Aldershot: Ashgate

Bruera, E., Willey, J. S., Palmer, J. L. and Rosales, M. 2002. ‘Treatment decisions for breast carcinoma-patient preferences and physician perceptions’, Cancer 94(7): 2076–80CrossRefGoogle ScholarPubMed

Buchanan, A., Califano, A., Kahn, J., McPherson, E., Robertson, J. and Brody, B. 2002. Pharmacogenetics: Ethical and Regulatory Issues in Research and Clinical Practice. Report of the Consortium on Pharmacogenetics. Findings and Recommendations. http://www.bioethics.umn.edu/News/pharm_report.pdf

Bullock, R. 2002. ‘New drugs for Alzheimer's disease and other dementias’, British Journal of Psychiatry 180: 135–9CrossRefGoogle ScholarPubMed

Butler, R. N. 1994. ‘ApoE: new risk factor for Alzheimer's’, Geriatrics 49(8): 10–11Google ScholarPubMed

Cacabelos, R., Alvarez, A., Lombardi, A., Fernandez-Novoa, L., Corzo, L., Perez, P., Laredo, M., Pichel, V., Hernandez, A., Varela, M., Figueroa, J., Prous, J., Windisch, M. and Vigo, C. 2000. ‘Pharmacological treatment of Alzheimer's disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics’, Drugs of Today 36(7): 415–99Google ScholarPubMed

Cambrosio, A. and Keating, P. 1995. Exquisite Specificity. The Monoclonal Antibody Revolution. Oxford: Oxford University Press

Carlsson, M. 2000. ‘Cancer patients seeking information from sources outside the health care system’, Supportive Care in Cancer 8(6): 453–7Google ScholarPubMed

Casamayou, M. H. 2001. The Politics of Breast Cancer. Washington, DC: Georgetown University Press

Chadwick, R. 1999. ‘Criteria for genetic screening: the impact of pharmaceutical research’, Monash Bioethics Review 18(1): 22–6CrossRefGoogle Scholar

Chamberlain, J. C. and Joubert, P. H. 2001. ‘Opportunities and strategies for introducing pharmacogenetics into early drug development’, Drug Discovery Today 6(11): 569–74CrossRefGoogle ScholarPubMed

Chen, D. T., Miller, F. G. and Rosenstein, D. L. 2003. ‘Clinical research and the physician–patient relationship’, Annals of Internal Medicine 138(8): 669–72CrossRefGoogle ScholarPubMed

Clarke, A., English, V., Harris, H. and Wells, F. 2001. ‘Report on ethical Considerations’, International Journal of Pharmaceutical Medicine 15: 89–94CrossRefGoogle Scholar

Coats, A. 2000. ‘Pharmacogenomics: hope or hype?’, International Journal of Cardiology 76: 1–3Google ScholarPubMed

Cockett, M., Dracopoli, N. and Sigal, E. 2000. ‘Applied genomics: integration of the technology within pharmaceutical research and development’, Current Opinion in Biotechnology 11: 602–9CrossRefGoogle ScholarPubMed

Collins, H. 1985. Changing Order: Replication and Induction in Scientific Practice. London: Sage

Collins, H. 1999. ‘Tantalus and the aliens: publications, audiences and the search for gravitational waves’, Social Studies of Science 29(2): 163–97CrossRefGoogle Scholar

Connor, S. 1999. ‘Genetic blueprint to predict illness’, Independent, 15 April, p. 10Google Scholar

Connor, S. 2003a. ‘Glaxo chief: Our drugs do not work on most patients’. Independent, 8 December, p. 1Google Scholar

Connor, S. 2003b. ‘Demolished: the myth that allows drugs giants to sell more’. Independent, 8 December, p. 8Google Scholar

Cook-Deegan, R. 1998. ‘Some questions arising in the commercial development of genetic tests for Alzheimer's disease’, in S. Post and P. Whitehouse (eds.), Genetic Testing for Alzheimer Disease: Ethical and Clinical Issues. Baltimore: Johns Hopkins University Press, pp. 84–100

Cookson, C. 1999. ‘Future cancer research may emphasise control not cure’, Financial Times, 18 September, p. 7Google Scholar

Corrigan, O. 2002. ‘A risky business: the detection of adverse drug reactions in clinical trials and post-marketing exercises’, Social Science and Medicine 55(3): pp. 497–507CrossRefGoogle ScholarPubMed

Cronin, M. T., Pho, M., Dutta, D., Frueh, F., Schwarcz, L. and Brennan, T. 2001. ‘Utilization of new technologies in drug trial and discovery’, Drug Metabolism and Disposition 29(4 part 2): 586–90Google ScholarPubMed

Cummings, J. L. 2003. ‘Use of cholinesterase inhibitors in clinical practice’, American Journal of Geriatric Psychiatry 11(2): 131–45CrossRefGoogle ScholarPubMed

Cummins, F. 2002. ‘Breast cancer NHS pill’, Mirror, 16 March, p. 8Google Scholar

Cunning, A. M. and Robertson, F. W. 1984. ‘Polymorphism at the apolipoprotein E locus in relation to risk of coronary disease’, Clinical Genetics 25: 310–13CrossRefGoogle Scholar

Czaban, J. N. 2001. ‘Pharmacogenomics: the uncertain path to decoding the regulatory genome’, Food and Drug Law Institute Update 3: 33Google Scholar

Day, M. 2002. ‘Women to win cancer drug fight’, Express, 15 March, p. 23Google Scholar

Department of Health 1999. ‘NICE proposals launched today: patients get faster access to modern treatment’, press release, 3 February

Department of Health 2003. Our Inheritance, Our Future. Realising the Potential of Genetics in the NHS. London: HMSO.

Department of Health 2003. The NHS Cancer Plan. Three Year Progress Report. Maintaining the Momentum. London: HMSO.

Diederich, F. 2002. ‘Nanotechnology – separating hype from reality’, Chemical Engineer Dec.: 26Google Scholar

DiMasi, J. A., Hansen, R. W., Grabowski, H. G. and Lasagna, L. 1991. ‘Cost of innovation in the pharmaceutical industry’, Journal of Health Economics 10: 107–42CrossRefGoogle ScholarPubMed

DiMasi, J. A., Hansen, R. W. and Grabowski, H. G. 2003. ‘The price of innovation: new estimates of drug development costs’, Journal of Health Economics 22: 151–85CrossRefGoogle Scholar

Drazen, J. M., Yandava, C. N., Dube, L.., Szczerback, N., Hippensteel, R., Pillari, A., Israel, E., Schork, N, Silverman, E. S., Katz, D. A. and Drajesk, J. 1999. ‘Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment’, Nature Genetics 22: 168–70CrossRefGoogle ScholarPubMed

Economist, 1997. ‘Drug companies’ target practice', Economist, 6 December, pp. 94–5Google Scholar

Einsiedel, E. F. and Eastlick, D. L. 2000. ‘Consensus conferences as deliberative democracy – a communications perspective’, Science Communication 21(4): 323–43CrossRefGoogle Scholar

Elder, A. T. and Fox, K. A. A. 1992. ‘Thrombolytic treatment for elderly patients’, British Medical Journal 305: 846–7CrossRefGoogle ScholarPubMed

Ellis, I. O., Dowsett, M., Bartlett, J., Walker, R., Cooke, T., Gullick, W., Gusterson, B., Mallon, E. and Barrett Lee, P. 2000. ‘Recommendations for HER2 testing in the UK’, Journal of Clinical Pathology 53: 890–2CrossRefGoogle ScholarPubMed

EMEA 2000. Report to the CPMP on the EMEA Seminar on the use of Pharmacogenetics in the Drug Development Process. 5 June. London: EMEA

Emery, J. and Hayflick, S. 2001. ‘The challenge of integrating genetic medicine into primary care’, British Medical Journal 322: 1027–30CrossRefGoogle ScholarPubMed

Emilien, G., Ponchon, M., Caldas, C., Isacson, O. and Maloteaux, J. M. 2000. ‘Impact of genomics on drug discovery and clinical medicine’, Quarterly Journal of Medicine 93(7): 391–423CrossRefGoogle ScholarPubMed

Ensom, M. H. H., Chang, T. H. K. and Patel, P. 2001. ‘Pharmacogenetics: the therapeutic drug monitoring of the future’, Clinical Pharmacokinetics 40(11): 783–802CrossRefGoogle Scholar

Epstein, S. 1996. Impure Science: AIDS, Activism and the Politics of Knowledge. Berkeley: University of California Press

Evans, W. E. and Relling, M. 1999. ‘Pharmacogenomics: translating functional genomics into rational therapeutics’, Science 286: 487–91CrossRefGoogle ScholarPubMed

Evans, W. E. and Johnson, J. A. 2001. ‘Pharmacogenomics: the inherited basis for interindividual differences in drug response’, Annual Review of Genomics and Human Genetics 2: 9–39CrossRefGoogle ScholarPubMed

Evans, W. E. and McLeod, H. L. 2003. ‘Pharmacogenomics – drug disposition, drug targets and side effects’, New England Journal of Medicine 348(6): 538–49CrossRefGoogle ScholarPubMed

Farlow, M., Gracon, S., Hershey, L., Lewis, K., Sadowsky, C. and Dolanureno, J. 1992. ‘A controlled trial of Tacrine in Alzheimer's disease’, Journal of the American Medical Association 268( 18): 2523–9CrossRefGoogle Scholar

Farlow, M., Lahiri, D. K., Poirier, J., Davignon, J. and Hui, S. 1996. ‘Apolipoprotein E genotype and gender influence response to tacrine therapy’, Annals of the New York Academy of Science 802: 101–10CrossRefGoogle Scholar

Farlow, M., Lahiri, D. K., Poirier, J.., Davignon, J., Schneider, L. and Hui, S. L. 1998. ‘Treatment outcome of tacrine therapy depends on apolipoprotein E genotype and gender of the subject with Alzheimer's disease’, Neurology 50: 669–77CrossRefGoogle Scholar

Farrer, L. A., Brin, M. F., Elsas, L., Goate, A., Kennedy, J., Mayeux, R., Myers, R. H., Reilly, P. and Risch, N. J. 1995. ‘Statement on use of apolipoprotein-E testing for Alzheimer-disease’, Journal of the American Medical Association 274 (20): 1627–9CrossRefGoogle Scholar

FDA 1991. ‘Tacrine as a treatment for Alzheimer's dementia: an interim report from the FDA’, New England Journal of Medicine 324(5): 349–52

Feldman, A. M., Lorell, B. H. and Reis, S. E. 2000. ‘Trastuzumab in the treatment of metastatic breast cancer’, Circulation 102: 272–4CrossRefGoogle ScholarPubMed

Feltham, C. 2002. ‘Pioneer's bright vision for new age of medicine’, Daily Mail, 10 October, p. 81Google Scholar

Fentiman, I. S. 1998. Detection and Treatment of Breast Cancer. 1st edn. London: Martin Dunitz

Ferentz, A. E. 2002. ‘Integrating pharmacogenomics into drug development’, Pharmacogenomics 3(4): 453–67CrossRefGoogle ScholarPubMed

Ferguson, J. H. 1996. ‘The NIH consensus development program: the evolution of guidelines’, International Journal of Technology Assessment in Health Care 12(3): 460–74Google ScholarPubMed

Financial Times (FT) 1994. ‘Alzheimer's drug hope for sufferers’, Financial Times, 6 April, p. 9

Financial Times (FT) 1997. ‘FT guide to: Genetic engineering’, Financial Times, 29 September, p. 10

Financial Times (FT) 2001. ‘Inside track’, Financial Times, 12 July, p. 10

Firn, D. 2000. ‘EU gives approval for Roche cancer treatment’, Financial Times, 31 August, p. 31Google Scholar

Fogarty, M. 1998. ‘Up for adoption: pharmacogenetics and the orphan drug law’, HMS Beagle 44, http://news.bmn.com/hmsbeagle/44/people/op_ed.htmGoogle Scholar

Fortun, M. 1998. ‘Sixty-five roses, Pulmozyme. Steve Shak, Genentech Inc.’, in G. E. Marcus, (ed.), Late Edition 5: Corporate Futures. Chicago: University of Chicago Press, pp. 209–42

Fortun, M. 2001. ‘Mediated speculations in the genomics futures markets’, New Genetics and Society 20(2): 139–56CrossRefGoogle Scholar

Fox, R. C. and Swazey, J. P. 1984. ‘Medical morality is not bioethics – medical ethics in China and the United States’, Perspective in Biology and Medicine 27(3): 336–60CrossRefGoogle Scholar

Frank, R. G. 2003. ‘Editorial: New estimates of drug development costs’, Journal of Health Economics 22: 325–30CrossRefGoogle ScholarPubMed

Franz, S. and Smith, A. 2003. ‘New drug approvals for 2002’, Nature Reviews Drug Discovery 2: 95–6CrossRefGoogle Scholar

Freedman, B. 1987. ‘Equipoise and the ethics of clinical research’, New England Journal of Medicine 317(3): 141–5CrossRefGoogle ScholarPubMed

Freeman, C. and Soefe, L. 1997. The Economics of Industrial Innovation. 3rd edn. London: Cassell

Frisoni, G. B. 2001. ‘Treatment of Alzheimer's disease with acetylcholinesterase inhibitors: bridging the gap between evidence and practice’, Journal of Neurology 248: 551–7CrossRefGoogle ScholarPubMed

Frith, M. 2003. ‘Reid orders inquiry into postcode drug prescribing’, Independent, 29 October, p. 6Google Scholar

Frost, S., Myers, L. B. and Newman, S. P. 2001. ‘Genetic screening for Alzheimer's disease: what factors predict intentions to take a test?’, Behavioral Medicine 27(3): 101–9CrossRefGoogle ScholarPubMed

GeneWatch, 2003. Pharmacogenetics: Better, Safer Medicines? Briefing number 23

GenomeWeb 2001. ‘Pharmacogenomics seen growing to $6B by 2005, report says’, http://www.genomeweb.com/articles/view.asp? Article no. 20017355957

Ginsburg, G. and McCarthy, J. 2001. ‘Personalized medicine: revolutionizing drug discovery and patient care’, Trends in Biotechnology 19(12): 491–9CrossRefGoogle ScholarPubMed

Glaser, V. 1998. ‘Pharmacogenomics: laying the foundation for prescriptive medicine’, Genetic Engineering News, 1 January, pp. 1, 9, 31 and 39Google Scholar

Gonzalez, F. J., Skoda, R. C., Kimura, S., Umeno, M., Zanger, U. M., Nebert, D. W., Gelboin, H. Y., Hardwick, J. P. and Meyer, U. A. 1988. ‘Characterization of the common genetic-defect in humans deficient in debrisoquine metabolism’, Nature 331(6155): 442–6CrossRefGoogle ScholarPubMed

Goodman, J. and Walsh, V. 2001. The Story of Taxol: Nature and Politics in the Pursuit of an Anti-Cancer Drug. Cambridge: Cambridge University Press

Gottlieb, S. 2000. ‘Cancer drug may cause heart failure’, British Medical Journal 321: 259Google ScholarPubMed

Graydon, J., Galloway, S., Palmer, Wickham S., Harrison, D., Richvanbder Bij, L., West, P., Burlein Hall, S. and Evans, Boyden B. 1997. ‘Information needs of women during early treatment for breast cancer’, Journal of Advanced Nursing 26(1): 59–64CrossRefGoogle ScholarPubMed

Green, M. C., Murray, J. L. and Hortobagyi, G. N. 2000. ‘Monoclonal antibody therapy for solid tumors’, Cancer Treatment Reviews 26: 269–86CrossRefGoogle ScholarPubMed

Griffith, V. 2000. ‘Mammoth task to untangle the genome: interpreting the genome’, Financial Times, 15 November, Biotechnology supplement, p. 2Google Scholar

Griffith, V. 2001. ‘Tailored care for cancer patients genetics’, Financial Times, 3 May, p. 10Google Scholar

Griffith, V. 2003a. ‘Breakthrough in tailor-made medicines. ASCO Conference’, Financial Times, 2 June, p. 26Google Scholar

Griffith, V. 2003b. ‘Optimistic Genentech reports earnings increase’, Financial Times, 16 January, p. 18Google Scholar

Growden, J. H. 1998. ‘Editorial: Apolipoprotein E and Alzheimer disease’, Archives of Neurology 55: 1053–4CrossRefGoogle Scholar

Guardian, , 2003. ‘Roche's biggest sellers’, Guardian, 27 February, p. 28Google Scholar

Guice, J. 1999. ‘Designing the future: the culture of new trends in science and technology’, Research Policy 28: 81–98CrossRefGoogle Scholar

Guston, D. H. 1999. ‘Evaluating the first US consensus conference: the impact of the citizens’ panel on telecommunications and the future of democracy', Science, Technology and Human Values 24(4): 451–82CrossRefGoogle Scholar

Hack, T. F., Degner, L. F. and Dyck, D. G. 1994. ‘Relationship between preferences for decisional control and illness information among women with breast cancer’, Social Science and Medicine 39: 279–89CrossRefGoogle ScholarPubMed

Hall, C. 1995. ‘Makers appeal for Alzheimer's drug licence’, Independent, 22 March, p. 4Google Scholar

Hamilton, A. and Piccart, M. 2000. ‘The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2’, Annals of Oncology 11: 647–63CrossRefGoogle ScholarPubMed

Harrison, S. 1998. ‘The politics of evidence-based medicine in the United Kingdom’, Policy and Politics 26(1): 15–31CrossRefGoogle Scholar

Haseltine, W. 1998. ‘Letter: Not quite pharmacogenomics’, Nature Biotechnology 16(12): 1295CrossRefGoogle ScholarPubMed

Hawkes, N. 2002. ‘£15,500 breast cancer drug to be free on NHS’ The Times, 16 March, p. 6Google Scholar

Hedgecoe, A. 2003. ‘Terminology and the construction of scientific disciplines: the case of pharmacogenomics’, Science, Technology and Human Values 28(4): 513–37CrossRefGoogle Scholar

Hedgecoe, A. and Martin, P. 2003. ‘The drugs don't work: expectations and the shaping of pharmacogenetics’, Social Studies of Science 33(3): 327–64CrossRefGoogle ScholarPubMed

Herrman, N., Sadavoy, J. and Steingart, A. 1987. ‘Letter’, New England Journal of Medicine 316(25) 1603–4Google Scholar

Highfield, R. 2001. ‘Genetic scientists in commercial row over “Book of Life”’, Daily Telegraph, 13 February, p. 14Google Scholar

Highfield, R. 2002. ‘500,000 to provide DNA samples for “biobank”’, Daily Telegraph, 29 April, p. 6Google Scholar

Hoban, C. J. 2002. ‘From the lab to the clinic: integration of pharmacogenetics into clinical practice’, Pharmacogenomics 3(4): 429–36CrossRefGoogle Scholar

Hortobagyi, G. N. and Perez, E. A. 2001. ‘Integration of Trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials’, Seminars in Oncology 28(5), supplement 16: 41–6CrossRefGoogle ScholarPubMed

Houghton, J. and Tobias, J. S. 2001. ‘Adjuvant radiotherapy in the management of early breast cancer’, in J. S. Tobias, J. Houghton and I. C. Henderson (eds.), Breast Cancer: New Horizons in Research and Treatment. London: Edward Arnold. pp. 189–94

Housman, D. and Ledley, F. 1998. ‘Why pharmacogenomics? Why now?’, Nature Biotechnology 16: 492–3CrossRefGoogle ScholarPubMed

Hughes, D. and Griffiths, L. 1997. ‘“Ruling in” and “ruling out”: two approaches to the micro-rationing of health care’, Social Science and Medicine 44(5): 589–99CrossRefGoogle ScholarPubMed

Hughes, T. P. 1983. Networks of Power: Electrification in Western Society 1880–1930. Baltimore: Johns Hopkins University Press

Hunt, L. 1996. ‘Unravelling the tangles of dementia’, Independent on Sunday, 28 April, Sunday Review, p. 42Google Scholar

Hurst, J. 1998. ‘The impact of health economics on health policy in England, and the impact of health policy on health economics 1972–1977’, Health Economics 7: S47–S62CrossRefGoogle Scholar

Hutton, J. and Maynard, A. 2000. ‘A NICE challenge for health economics’, Health Economics 9: 89–933.0.CO;2-G>CrossRefGoogle ScholarPubMed

Hyman, B. T. and Wallace, R. B. 1997. ‘Reply’, Annals of Neurology 41(3): 415–16CrossRefGoogle Scholar

Independent 2000. ‘Genome challenge’, Independent, 28 June, p. 20

Independent 2003. ‘Leader: Multinational drug company: honest, decent, public-spirited?’, Independent, 8 December, p. 16

Ingelman-Sundberg, M. 2001. ‘Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy’, Journal of Internal Medicine 250: 186–200CrossRefGoogle ScholarPubMed

Irwin, A. and Wynne, B. 1996. Misunderstanding Science? The Public Reconstruction of Science and Technology. Cambridge: Cambridge University Press

Issa, A. M. 2000. ‘Ethical considerations in clinical pharmacogenomics research’, Trends in Pharmacological Science 21: 247–9CrossRefGoogle ScholarPubMed

Issa, A. M. 2002. ‘Ethical perspectives on pharmacogenomic profiling in the drug development process’, Nature Reviews Drug Discovery 1(4): 300–8CrossRefGoogle ScholarPubMed

Issa, A. M. and Kegserlingk, E. W. 2000. ‘Apolipoprotein E genotyping for pharmacogenetic purposes in Alzheimer's disease: emerging ethical issues’, Canadian Journal of Psychiatry 45: 917–2CrossRefGoogle ScholarPubMed

Jacoby, I. 1985. ‘Editorial: The consensus development program of the National Instititues of Health’, American Journal of Psychiatry 142(4): 477–8Google Scholar

James, R. J. 2002. ‘Commentary on Kewell et al. (2002), Calman-Hine reassessed’, Journal of Evaluation in Clinical Practice 8(3): 299–301Google Scholar

Jazwinska, E. C. 2001. ‘Exploiting human genetic variation in drug discovery and development’, Drug Discovery Today 6(4): 198–205CrossRefGoogle ScholarPubMed

Jenkins, P. 2002. ‘The future is made-to-measure: pharmacogenomics’, Financial Times, 30 April, Survey section, p. 3Google Scholar

Johnson, J. A. and Evans, W. E. 2002. ‘Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity’, Trends in Molecular Medicine 8(6): 300–5CrossRefGoogle ScholarPubMed

Johnston, L. 2001. ‘Scandal of the vital life-saving treatments that NHS won't buy’, Sunday Express, 29 July, p. 11Google Scholar

Jordan, K. and Lynch, M. 1998. ‘The dissemination, standardization and routinization of a molecular biological technique’, Social Studies of Science 28(5–6): 733–800CrossRefGoogle Scholar

Jordan, V. C. 2003. ‘Tamoxifen: a most unlikely pioneering medicine’, Nature Reviews Drug Discovery 2: 205–13CrossRefGoogle ScholarPubMed

Joss, S. and Bellucci, S. (eds.) 2002. Participatory Technology Assessment. European Perspectives. London: CSD and TA Swiss

Kakulas, B. A. and Bockxmeer, F. M. 1995. ‘Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: a cautionary view’, Annals of Neurology 38(6): 966–7CrossRefGoogle Scholar

Kalow, W. 1990. ‘Pharmacogenetics: past and future’, Life Sciences 47: 1385–97CrossRefGoogle ScholarPubMed

Kandohla, T. 2002. ‘Deadly delay’, Sun, 16 March, p. 29Google Scholar

Kaptain, S., Tan, L. K. and Chen, B. 2001. ‘Her-2/ neu and breast cancer’, Diagnostic Molecular Pathology 10(3): 139–52CrossRefGoogle ScholarPubMed

Kendall, P. 2001. ‘Tailor-made drugs to combat cancer’, Daily Mail, 22 February, p. 39Google Scholar

Kewell, B., Hawkins, C. and Ferlie, E. 2002. ‘Calman–Hine reassessed: a survey of cancer network development in England, 1999–2000’, Journal of Evaluation in Clinical Practice 8(3): 303–11Google Scholar

Klawiter, M. 2000. ‘Racing for the cure, walking women and toxic touring: mapping cultures of action within the Bay area terrain of breast cancer’, in Potts L. K. (ed.) Ideologies of Breast Cancer: Feminist Perspectives. London: Macmillan, pp. 63–97

Klein, R. 2001. The New Politics of the National Health Service. 4th edn. London: Prentice Hall

Klein, R., Day, P. and Redmayne, S. 1996. Managing Scarcity: Priority Setting and Rationing in the National Health Service. Milton Keynes: Open University Press

Kleyn, P. W. and Vesell, E. S. 1998. ‘Genetic variation as a guide to drug development’, Science 281: 1820–1CrossRefGoogle ScholarPubMed

Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey-Bloom, J., Relkin, N., Small, G. W., Miller, B. and Stevens, J. C. 2001. ‘Practitioner parameter: diagnosis of dementia (an evidence based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology’, Neurology 56: 1143–53CrossRefGoogle Scholar

Koenig, P. 1991. ‘Money and the medicine men’, Independent on Sunday, 12 May, Review section, p. 2Google Scholar

Koepp, R. and Miles, S. H. 1999. ‘Meta-analysis of Tacrine for Alzheimer disease: the influence of industry sponsors’, Journal of the American Medical Association 281(24) (June 23/30): 2287Google ScholarPubMed

Kolata, G. 1999. ‘Using gene tests to customize medical treatment’, New York Times, 20 December, Section A, p. 1Google ScholarPubMed

Koselleck, R. 1985. Futures Past: On the Semantics of Historical Time. Cambridge, MA: MIT Press

Krall, W. J., Sramek, J. J. and Cutler, N. R. 1999. ‘Cholinesterase inhibitors: a therapeutic strategy for Alzheimer's disease’, Annals of Pharmacology 33: 441–50CrossRefGoogle Scholar

Kuczewski, M. G. and Marshall, P. 2002. ‘The decision dynamics of clinical research: the context and process of informed consent’, Medical Care 40(9) special supplement: 45–54CrossRefGoogle ScholarPubMed

Kuivenhoven, J., Jukema, W., Zwinderman, A., Knijff, P., McPherson, R., Bruschke, A., Lie, K. and Kastelein, J. 1998. ‘The role of a common variant of the CETP gene in the progression of coronary artherosclerosis’, New England Journal of Medicine 338(2): 86–93CrossRefGoogle Scholar

Kumar, S. 1999. ‘Resisting revolution: generalism and the new genetics’, Lancet 354: 1992–3CrossRefGoogle ScholarPubMed

Kumar, S. and Gantley, M. 1999. ‘Tensions between policy makers and general practitioners in implementing new genetics: grounded theory interview study’, British Medical Journal 319: 1410–13CrossRefGoogle ScholarPubMed

Kurth, J. H. 2000. ‘Pharmacogenomics: future promise of a tool for identifying patients at risk’, Drug Information Journal 34: 223–7CrossRefGoogle Scholar

Lahiri, D. K., Farlow, M., Greig, N. H. and Sambamurti, K. 2002. ‘Current drug targets for Alzheimer's disease treatment’, Drug Development Research 56: 267–81CrossRefGoogle Scholar

Lanctôt, K. L., Hermann, N. and LouLou, M. M. 2003. ‘Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease’, Journal of Psychiatry and Neuroscience 28(1): 13–26Google ScholarPubMed

Lappin, T. 2001. ‘The year in ideas: A to Z – Pharmacogenomics’, New York Times, 9 December, section 6, p. 88Google Scholar

Larkin, M. 1997. ‘Allen Roses: “Enfant terrible” of Alzheimer's research’, Lancet 349: 1302CrossRefGoogle Scholar

Latour, B. 1987. Science in Action: How to Follow Scientists and Engineers Through Society. Cambridge, MA: Harvard University Press

Latour, B. 1988. The Pasteurization of France. Cambridge, MA: Harvard University Press

Lau, K. and Sakul, H. 2000. ‘Pharmacogenomics’, in A. M. Doherty (ed.), Annual Reports in Medicinal Chemistry. London and San Diego: Academic Press, pp. 261–9

Laurance, J. 2002. ‘£20,000-a-year cancer drug approved for NHS’, Independent, 16 March, p. 4Google Scholar

Lavori, P. W., Krause-Steinrauf, H., Brophy, M., Buxbaum, J., Cockroft, J., Cox, D. R., Fiore, L., Greely, H. T., Greenberg, H., Holmes, E. W., Nelson, L. M. and Sugarman, J. 2002. ‘Principles, organization, and operation of a DNA bank for clinical trials: a Department of Veterans Affairs cooperative study’, Controlled Clinical Trials 23(3): 222–39CrossRefGoogle ScholarPubMed

Law, J. 1987. ‘Technology and heterogeneous engineering: the case of Portuguese expansion’, in W. Bijker, T. Hughes and T. J. Pinch (eds.), The Social Construction of Technological Systems: New Directions in the Sociology and History of Technology. Cambridge, MA.: MIT Press, pp. 111–3

Lazarou, J., Pomeranz, B. H. and Corey, P. N. 1998. ‘Incidence of adverse drug reactions in hospitalized patients’, Journal of the American Medical Association 279(15): 1200–5CrossRefGoogle ScholarPubMed

Lebeau, A., Deimling, D., Kaltz, C., Sendelhofert, A., Iff, A., Luthardt, B., Untch, M. and Lohrs, U. 2001. ‘HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization’, Journal of Clinical Oncology 19(2): 354–63CrossRefGoogle ScholarPubMed

Lehman Brothers. 2001. The Fruits of Genomics. New York: Lehman Brothers

Lerner, B. H. 2001. The Breast Cancer Wars: Hope, Fear and the Pursuit of a Cure in Twentieth-Century America. Oxford: Oxford University Press

Leyland-Jones, B. 2002. ‘Trastuzumab: hopes and realities’, Lancet Oncology 3: 137–44CrossRefGoogle ScholarPubMed

Liggett, S. B. 2001. ‘Pharmacogenetic applications of the Human Genome Project’, Nature Medicine 7(3): 281–3CrossRefGoogle ScholarPubMed

Lindpaintner, K. 1999. ‘Genetics in drug discovery and development: challenge and promise of individualizing treatment in common complex disease’, British Medical Bulletin 55(2): 471–91CrossRefGoogle Scholar

Lindpaintner, K. 2002. ‘The importance of being modest – reflections on the pharmacogenetics of abacavir’, Pharmacogenomics 3(6): 835–8CrossRefGoogle ScholarPubMed

Lindpaintner, K. 2003. ‘Pharmacogenetics: a new – or not so new? – concept in healthcare’, Geneva Papers on Risk and Insurance 28(2): 316–30CrossRefGoogle Scholar

Lindpaintner, K., Foot, E., Caulfield, M. and Hall, I. 2001. ‘Pharmacogenetics: focus on pharmacodynamics’, International Journal of Pharmaceutical Medicine 15: 74–82CrossRefGoogle Scholar

Lipman, T. 2001. ‘Letter: NICE and evidence based medicine are not really compatible’, British Medical Journal 322: 489–90Google Scholar

Lipton, P. 2003. ‘Pharmacogenetics: the ethical issues’, Pharmacogenomics Journal 3: 14–16CrossRefGoogle ScholarPubMed

Littlejohns, P., Barnett, D. and Longson, C. 2003. ‘The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence’, Lancet Oncology 4: 242–50CrossRefGoogle ScholarPubMed

Lohrisch, C. and Piccart, M. 2001. ‘An overview of HER2’, Seminars in Oncology 28(6): 3–11CrossRefGoogle ScholarPubMed

Lovestone, S. 1998. ‘Letter: Genetics consortium can offer views facilitating best practice in Alzheimer's disease’, British Medical Journal 317: 471CrossRefGoogle Scholar

Lovestone, S., Wilcock, G., Rosser, M., Cayton, H. and Ragan, I. 1996. ‘Letter: apolipoprotein E genotyping in Alzheimer's disease’, Lancet 347: 1775–6Google ScholarPubMed

Lucotte, G., Oddoze, C. and Michel, B. F. 1995. ‘Apolipoprotein E and response to tacrine in French Alzheimer's disease patients’, abstract presented at the International Psychogeriatrics Association Conference, Apolipoprotein E et Maladie d'Alzheimer, 29 May, Paris

MacGowan, S. H., Scott, M., Agg, M. and Wilcock, G. 1995. ‘Influence of apolipoprotien E genotype on response to tacrine in male and female patients with Alzheimer's disease’, abstract presented at the International Psychogeriatrics Association Conference, Apoilpoprotien E et Maladie d'Alzheimer, 29 May, Paris

Macgowan, S. H., Wilcock, G. and Scott, M. 1998. ‘Effect of gender and apolopoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease’, International Journal of Geriatric Psychiatry 13: 625–303.0.CO;2-2>CrossRefGoogle Scholar

MacKenzie, D. 1990. Inventing Accuracy: A Historical Sociology of Nuclear Missile Guidance. Cambridge, MA: MIT Press

MacKenzie, D. 1998. ‘The certainty trough’, in R. Williams, W. Faulkner and J. Fleck (eds.), Exploring Expertise: Issues and Perspectives. London: Macmillan, pp. 325–9

MacKenzie, D. and Wajcman, J. (eds.) 1999. The Social Shaping of Technology. 2nd edn. Milton Keynes: Open University Press

Macklin, R. 1999. Against Relativism: Cultural Diversity and the Search for Ethical Universals in Medicine. Oxford: Oxford University Press

Maimone, D., Dominici, R. and Grimaldi, L. 2001. ‘Pharmacogenomics of neurodegenerative diseases’, European Journal of Pharmacology 413: 11–29CrossRefGoogle ScholarPubMed

Maitland-van der Zee, A. H., Boer, A. and Leufkens, H. G. M. 2000. ‘The interface between pharmacoepidemiology and pharmacogenetics’, European Journal of Pharmacology 410: 121–30CrossRefGoogle ScholarPubMed

Mancinelli, L., Cronin, M. and Sadée, W. 2000. ‘Pharmacogenomics: the promise of personalized medicine’, AAPS Pharmsci 2(1) (7 March): article 4CrossRefGoogle ScholarPubMed

March, R. 2000. ‘Pharmacogenomics: the genomics of drug response’, Yeast 17: 16–213.0.CO;2-E>CrossRefGoogle ScholarPubMed

March, R., Cheeseman, K. and Doherty, M. 2001. ‘Pharmacogenetics – legal, ethical and regulatory considerations’, Pharmacogenomics 2(4): 317–27CrossRefGoogle ScholarPubMed

Margolese, R. G. 2001. ‘Neoadjuvant systemic primary therapy – is surgery the true adjuvant?’, in J. S. Tobias, J. Houghton and I. C. Henderson (eds.), Breast Cancer: New Horizons in Research and Treatment. London: Edward Arnold, pp. 177–87

Marsh, B. 2001. ‘Breast cancer victim uses mother's £20,000 savings as NHS refuses to buy drug; how cruel postcode lottery denies a wife her “last chance” of survival’, Daily Mail, 27 December, p. 17Google Scholar

Marsh, B. 2003. ‘Thousands still dying in cancer postcode lottery’, Daily Mail, 29 October, p. 10Google Scholar

Marshall, A. 1997. ‘Getting the right drug into the right patient’, Nature Biotechnology 15: 1249–52CrossRefGoogle ScholarPubMed

Marshall, A. 1998. ‘Laying the foundations for personalized medicines’, Nature Biotechnology 16, supplement: 6–8CrossRefGoogle Scholar

Marshall, E. 1998. ‘Allen Roses: from “street-fighter” to corporate insider’, Science 280: 1001–4CrossRefGoogle Scholar

Martin, P. 1995. ‘The American gene therapy industry and the social shaping of a new technology’, Genetic Engineer and Biotechnologist 15(2–3): 155–67Google Scholar

Martin, P. 1999. ‘Genes as drugs: the social shaping of gene therapy and the reconstruction of genetic disease’, Sociology of Health and Illness 21: 517–38CrossRefGoogle Scholar

Maroc, J. 1993. ‘New Alzheimer's theory stirs controversy’, Science 262: 1210–11Google Scholar

Maslin, A. M. and Powles, T. 1999. Breast Cancer: Sharing the Decision. Oxford: Oxford University Press

Mayeux, R., Saunders, A. M., Shea, S., Mirra, S., Evans, D., Roses, A. D., Hyman, B. T., Crain, B., Tang, M. X. and Phelps, C. H. 1998. ‘Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease’, New England Journal of Medicine 338(8): 506–11CrossRefGoogle Scholar

McConnell, L. M., Koenig, B. A., Greely, H. T. and Raffin, T. A. 1998. ‘Genetic testing and alzheimer's disease: has the time come?’, Nature Medicine 4: 757–9CrossRefGoogle ScholarPubMed

McConnell, L. M., Sanders, G. D. and Owens, D. K. 1999. ‘Evaluation of genetic tests: APOE genotyping for the diagnosis of Alzheimer disease’ Genetic Testing 3(1): 47–53CrossRefGoogle Scholar

McKie, R. 1999. ‘Genetic key to personal medicines’, Observer, 5 December, p. 9Google Scholar

McLeod, H. L. and Evans, W. E. 2001. ‘Pharmacogenomics: unlocking the human genome for better drug therapy’, Annual Review of Pharmacology and Toxicology 41: 101–21CrossRefGoogle ScholarPubMed

McNeil, C. 1998. ‘Herceptin raises its sights beyond advanced breast cancer’, Journal of the National Cancer Institute 90(12): 882–3CrossRefGoogle ScholarPubMed

Medical Research Council 2003. ‘MRC response to the MHRA consultation letter on the Medicines for Human Use (Clinical Trials) Regulations 2003 (MLX 287) and draft legislation’. London: Medical Research Council

Merz, J. F., Cho, M. K. and Leonard, D. G. B. 1998. ‘Letter: testing for Alzheimer's’, Science 281: 1288–9CrossRefGoogle ScholarPubMed

Meyer, U. A. 1990. ‘Molecular genetics and the future of pharmacogenetics’, Pharmacological Therapies 46: 349–55CrossRefGoogle ScholarPubMed

Meyer, U. A. 2000 ‘Pharmacogenetics and adverse drug reactions’, Lancet 356: 1667–71CrossRefGoogle ScholarPubMed

Miles, D. W. 2001. ‘Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting’, Breast Cancer Research 3: 380–4CrossRefGoogle ScholarPubMed

Miller, S. and Gregory, J. 1998. Science in Public: Communication, Culture and Credibility. New York: Plenum

Mitchell, M. S. and Press, M. F. 1999. ‘The role of immunohistochemistry and fluorescence in situ hybridization for HER-2/neu in assessing the prognosis of breast cancer’, Seminars in Oncology 26(4), supplement 12: 108–16Google ScholarPubMed

Mokbel, K. and Hassanally, D. 2001. ‘From HER2 to herceptin’, Current Medical Research and Opinions 17(1): 51–9CrossRefGoogle ScholarPubMed

Møldrup, C. 2001. ‘Ethical, social and legal implications of pharmacogenomics: a critical review’, Community Genetics 4: 204–14Google ScholarPubMed

Moore, W. 2001. ‘Designer drugs: in less than a decade, tailor-made medication could make fatal side effects a thing of the past’, Observer, 15 April, p. 47Google Scholar

Moyses, C. 1999. ‘Pharmacogenetics, genomics, proteomics: the new frontiers in drug development’, International Journal of Pharmaceutical Medicine 13(4): 197–202Google Scholar

Mudher, A. and Lovestone, S. 2002. ‘Alzheimer's disease – do Tauists and Baptists finally shake hands?’, Trends in Neuroscience 25(1): 22–6CrossRefGoogle ScholarPubMed

Mullan, F. and Jacoby, I. 1985. ‘The town meeting for technology: the maturation of consensus conferences’, Journal of the American Medical Association 254(8): 1068–72CrossRefGoogle ScholarPubMed

Murphy, M. P. 2000. ‘Pharmacogenomics: a new paradigm for drug development’, Drug Discovery World (fall): 1–7Google Scholar

Murray, M. D. and Deardorff, F. W. 1998. ‘Does managed care fuel pharmaceutical industry growth?’, Pharmacoeconomics 14(4): 341–8CrossRefGoogle ScholarPubMed

Myers, G. 1990a. Writing Biology: Texts in the Social Construction of Scientific Knowledge. Madison, WI: University of Wisconsin Press

Myers, G. 1990b. ‘Making a discovery: narratives of split genes’, in C. Nash (ed.), Narrative in Culture. The Uses of Storytelling in the Sciences, Philosophy, and Literature. London: Routledge, pp. 102–25

Myers, G. 1991. ‘Stories and styles in two molecular biology review articles’, in C. Bazerman and J. Paradis (eds.), Textual Dynamics of the Professions. Madison, WI: University of Wisconsin Press, pp. 45–75

National Institute for Clinical Excellence 2001. ‘NICE issues guidance on drugs for Alzheimer's disease’, press release, 19 January

National Institute for Clinical Excellence 2002. Guidance on the Use of Trastuzumab for the Treatment of Advanced Breast Cancer. London: National Institute for Clinical Excellence

Nebert, D. W. 1997. ‘Pharmacogenetics: 65 candles on the cake’, Pharmacogenetics 7: 435–40CrossRefGoogle Scholar

Neumann, P. J., Hammitt, J. K., Mueller, C., Fillit, H. M., Hill, J., Tetteh, N. A. and Kosik, K. S. 2001. ‘Public attitudes about genetic testing for Alzheimer's disease’, Health Affairs 20(5): 252–64CrossRefGoogle ScholarPubMed

Newdick, C. 1995. Who Should We Treat?: Law, Patients and Resources in the NHS. Oxford: Clarendon

Nicoletto, M. O., Donach, M., Nicolo, A., Artioli, G., Banna, G. and Monfardini, S. 2001. ‘BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling’, Cancer Treatment Reviews 27: 295–304CrossRefGoogle ScholarPubMed

Norton, R. M. 2001. ‘Clinical pharmacogenomics: applications in pharmaceutical R&D’, Drug Discovery Today 6(4): 180–5CrossRefGoogle ScholarPubMed

Nuffield Council on Bioethics 2003. Pharmacogenetics. Ethical Issues: Report of Working Party. London: Nuffield Council on Bioethics

O'Connell, S. 2001. ‘Could medicines be made to measure?’, Independent, 31 August, p. 8Google Scholar

Oddoze, C., Michel, B. F., Berthezene, P., Clavel, C. and Lucotte, G. 1998. ‘Apolipoprotein E epsilon 4 allele predicts a positive response to tacrine in Alzheimer's disease’, Alzheimer's Report 1(1): 13–16Google Scholar

Oddoze, C., Michel, B. F. and Lucotte, G. 2000. ‘Apolipoprotein E epsilon 4 allele predicts a better response to donepezil therapy in Alzheimer's disease’, Alzheimer's Report 3(4): 213–16Google Scholar

Oestreicher, P. 2001. ‘4th Annual Pharmacogenomics and Medicine Lecture: 3 April 2001, New Haven, Connecticut’, Pharmacogenomics 2(3): 291–6CrossRefGoogle Scholar

Olson, J. S. 2002. Bathsheba's Breast: Women, Cancer and History. Baltimore: Johns Hopkins University Press

Pang, T. and Weatherall, D. 2002. ‘Genomics and global health: hype, reality, and a call for action in the developing and the developed world’, British Medical Journal 324: 1051–2CrossRefGoogle Scholar

Pauletti, G., Dandekar, S., Rong, H. M., Ramos, L., Pong, H. J., Seshadri, R. and Slamon, D. J. 2000. ‘Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry’, Journal of Clinical Oncology 18(21): 3651–64CrossRefGoogle Scholar

Paul, J. E. and Trueman, P. 2001. ‘Fourth hurdle reviews, NICE, and database applications’, Pharmacoepidemiology and Drug Safety 10: 429–38CrossRefGoogle ScholarPubMed

Paulson, H. L. 2002. ‘Diagnostic testing in neurogenetics. Principles, limitations, and ethical considerations’, Neurologic Clinics of North America 20: 627–43Google ScholarPubMed

Perez, E. A. and Hortobagyi, G. N. 2000. ‘Ongoing and planned adjuvant trials with trastuzumab’, Seminars in Oncology 27(6), Supplement 11: 26–32Google ScholarPubMed

Perlman, D. 1999. ‘Stubborn scientists, heroic women lead to a cancer breakthrough’, San Francisco Chronicle, 17 January, Sunday Review, p. 5Google Scholar

Perry, S. 1987. ‘The NIH Consensus development program: a decade later’, New England Journal of Medicine 317(8): 485–8CrossRefGoogle ScholarPubMed

Persing, B. F. and Cheek, D. J. 2000. ‘Pharmacogenomics’, Nursing Clinics of North America 35(4): 975–80Google ScholarPubMed

Pfost, D. R., Boyce-Jacino, M. T. and Grant, D. M. 2000. ‘A SNPshot: pharmacogenetics and the future of drug therapy’, Trends in Biotechnology 18: 334–8CrossRefGoogle ScholarPubMed

Pharma, Marketletter, 1993. ‘HMO excludes Cognex from formulary’, Pharma Marketletter, 4 OctoberGoogle Scholar

Pharma, Marketletter, 1999. ‘SB licences Memris to UK biotech Cerebrus’, Pharma Marketletter, 1 JuneGoogle Scholar

Pharmaceutical Business News 1994. ‘Athena Neurosciences to acquire Genica Pharmaceuticals’, Pharmaceutical Business News, 21 December

Phillips, K., Veenstra, D., Oren, E., Lee, L. and Sadée, W. 2001. ‘Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review’, Journal of the American Medical Association, 286(18): 2270–9CrossRefGoogle ScholarPubMed

Piccart, M. and Kaufman, M. 2001. ‘Introduction’, European Journal of Cancer 37: S1–S2CrossRefGoogle ScholarPubMed

Pilling, D. 1999a. ‘Drug group in drive for cancer breakthrough’, Financial Times, 11 November, p. 14Google Scholar

Pilling, D. 1999b. ‘Smarter weapons to combat cancer’, Financial Times, 12 November, Comment and Analysis section, p. 21Google Scholar

Pilling, D. 2000. ‘Uncertainty prefaces book of life’, Financial Times, 18 December, Weekend section, p. 1Google Scholar

Pinch, (T. J. and Bijker, (W. E. 1987. ‘The social construction of facts and artefacts – or how the sociology of science and the sociology of technology might benefit each other’, in Bijker, Hughes & Pinch 1987

Pinch, T., Ashmore, M. and Mulkay, M. 1992. ‘Technology, testing, text: clinical budgeting in the UK National Health Service’, in W. Bijker and J. Law, (eds.), Shaping Technology/Building Society: Studies in Sociotechnical Change. Cambridge, MA: MIT Press, pp. 265–89

Pirmohamed, M. and Park, B. K. 2001. ‘Genetic susceptibility to adverse drug reactions’, Trends in Pharmacological Sciences 22(6): 298–305CrossRefGoogle ScholarPubMed

Pirmohamed, M. and Park, B. K. 2003. ‘Adverse drug reactions: back to the future’, British Journal of Clinical Pharmacology 55(5): 486–92CrossRefGoogle ScholarPubMed

Poirier, J. 1999a. ‘Apolipoprotein E: a pharmacogenetic target for the treatment of Alzheimer's disease’, Molecular Diagnosis 4(4): 335–41CrossRefGoogle Scholar

Poirier, J. 1999b. ‘Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease’, Journal of Psychiatry and Neuroscience 24(2): 147–53Google Scholar

Poirier, J., Delisle, M. C., Quirion, R., Aubert, I., Farlow, M., Lahiri, D., Hui, S., Bertrand, P., Nalbantoglu, J., Gilfix, B. M. and Gauthier, S. 1995. ‘Apolipoprotein E allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease’, Proceedings of the National Academy of Sciences 92: 12260–4CrossRefGoogle ScholarPubMed

Pollack, A. 1999. ‘In the works: drugs tailored to individual patients’, New York Times, 20 December, Section C, p. 8Google Scholar

Pollack, A. 2000. ‘Talking biotechnology with: George Rathmann’, New York Times, 18 December, Section C, p. 3Google Scholar

Pollack, A. 2002. ‘New era of consumer genetics raises hope and concerns’, New York Times, 1 October, Section F, p. 5Google Scholar

Post, S. G. 1996. ‘On not jumping the gun: ethical aspects of APOE gene testing for Alzheimer's disease’, in (N. R. Relkin, Z. Khachaturian and S. Gandy, (eds.), Apolipoprotein E Genotyping in Alzheimer's Disease: Annals of the New York Academy of Sciences. vol. 802. New York: New York Academy of Science

Post, S. G., Whitehouse, P. J., Binstock, R. H., Bird, T. D., Eckert, S. K., Farrer, L. A., Fleck, L. M., Gaines, A. D., Jeungst, E. T., Karlinsky, H., Miles, S., Murray, T. D., Quaid, K. A., Relkin, N. R., Roses, A. D., Georgehyslop, P. H. S., Sachs, G. A., Steinbock, B., Truschke, E. F. and Zinn, A. B. 1997. ‘The clinical introduction of genetic testing for alzheimer disease – an ethical perspective’, Journal of the American Medical Association 277(10): 832–6CrossRefGoogle ScholarPubMed

Pricewaterhouse, Coopers 1998. Pharma 2005: An Industrial Revolution in R&D, http://www.pwcglobal.com/gx/eng/about/ind/pharma/industrial_revolution.pdf

Qizilibash, N., Whitehead, A., Higgins, J., Wilcock, G., Schneider, L. and Farlow, M. 1998. ‘Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the Tacrine trials’, Journal of the American Medical Association 280(20): 1777–82CrossRefGoogle Scholar

Radford, T. 2003. ‘On the edge of a genetic revolution to map out medical future at birth’, Guardian, 25 June, p. 3Google Scholar

Rampaul, R. S., Pinder, S. E., Gullick, W. J., Robertson, J. F. R. and Ellis, I. O. 2002. ‘HER-2 in breast cancer – methods of detection, clinical significance and future prospects for treatment’, Critical Reviews in Oncology/Hematology 43: 231–44CrossRefGoogle Scholar

Rapp, R. 2000. Testing Women, Testing the Fetus: The Social Impact of Amniocentesis in America. New York: Routledge

Raskind, M. A., Peskind, E. R., Wessel, T. and Yuan, W. 2000. ‘Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension’, Neurology 54: 2261–8CrossRefGoogle ScholarPubMed

Regalado, A. 1999. ‘Inventing the pharmacogenomics business’, American Journal of Health-System Pharmacy 56: 40–50Google ScholarPubMed

Reichert, J. M. 2001. ‘Monoclonal antibodies in the clinic’, Nature Biotechnology 19: 819–22CrossRefGoogle ScholarPubMed

Reichert, J. M. 2003. ‘Trends in development and approval times for new therapeutics in the United States’, Nature Reviews Drug Discovery 2: 695–702CrossRefGoogle ScholarPubMed

Relkin, N. R., Kwon, Y. J., Tsai, J. and Gandy, S. 1996a. ‘Consensus statement: apolipoprotein E genotyping in Alzheimer's disease’, Lancet 347: 1091–5CrossRefGoogle Scholar

Relkin, N. R., Kwon, Y. J., Tsai, J. and Gandy, S. 1996b. ‘The National Institute on Aging/Alzheimer's Association recommendations on the application of apolipoprotein E genotyping to Alzheimer's disease’, Annals of the New York Academy of Sciences 802: 149–71CrossRefGoogle Scholar

Relman, A. S. and Angell, M. 2002. ‘America's other drug problem: how the drug industry distorts medicine and politics’, New Republic, 16 December: 27–41Google ScholarPubMed

Rennie, D. 1981. ‘Consensus statements’, New England Journal of Medicine 304(11): 665–6CrossRefGoogle ScholarPubMed

Richard, F., Helbecque, N., Neuman, E., Guez, D., Levy, R. and Amouyel, P. 1997. ‘APOE genotyping and response to drug treatment in Alzheimer's disease’, Lancet 349: 539CrossRefGoogle ScholarPubMed

Richard, F. and Amouyel, P. 2001. ‘Genetic susceptibility factors for Alzheimer's disease’, European Journal of Pharmacology 412: 1–12CrossRefGoogle ScholarPubMed

Riekkinen, P. J., Koivisto, K. and Reinikaianen, (K. J. et al. 1998. ‘Can apo-4 subtype predict response to selegiline treatment in Alzheimer's disease?’, in E. Giacobini, A. Nordberg, J-P. Michel, B. Winblad and R. Becker (eds.), Proceedings of the 5th International Geneva/Springfield Symposium on Advances in Alzheimer's Therapy. Springfields, IL: Southern Illinois University Press, p. 91

Rigaud, A. S., Traykov, L., Caputo, L., Guelfi, M. C., Latour, F., Couderc, R., Moulin, F., Rotrou, J., Forette, F. and Boller, F. 2000. ‘The apolipoprotein E ∊4 allele and the response to tacrine therapy in Alzheimer's disease’, European Journal of Neurology 7: 255–8CrossRefGoogle ScholarPubMed

Rioux, P. 2000. ‘Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications’, American Journal of Health System Pharmacy 57(9): 887–98Google ScholarPubMed

Ritchie, K. and Lovestone, S. 2002. The dementias, Lancet 360(9347): 1759–66CrossRefGoogle ScholarPubMed

Roberts, F. D. 1999. Talking about Treatment: Recommendations for Breast Cancer Adjuvant Therapy. Oxford: Oxford University Press

Roberts, J. S. 2000. ‘Anticipating response to predictive testing for Alzheimer's disease: a survey of first-degree relatives’, Gerontologist 40(1): 43–52Google ScholarPubMed

Robertson, J. 2001. ‘Consent and privacy in pharmacogenetic testing’, Nature Genetics 28(3): 207–9CrossRefGoogle ScholarPubMed

Robertson, J. A., Brody, B., Buchanan, A., Kahn, J. and McPherson, E. 2002. ‘Pharmacogenetic challenges for the health care system’, Health Affairs 21(4): 155–67CrossRefGoogle ScholarPubMed

Roche, 2003. ‘Roche Diagnostics launches the AmpliChip’, press release, 25 June

Roden, D. M. and George, A. L. 2002. ‘The genetic basis of variability in drug responses’, Nature Reviews Drug Discovery 1: 37–44CrossRefGoogle ScholarPubMed

Rodwin, M. A. 2001. ‘The politics of evidence-based medicine’, Journal of Health Politics, Policy and Law 26(2): 439–46CrossRefGoogle ScholarPubMed

Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group 1998. ‘Consensus report of the Working Group on: “Molecular and Biochemical Maters of Alzheimer's Disease”’, Neurobiology of Aging 19(2): 109–16

Rose, S. 2003. ‘Science, not fiction’, Guardian, 15 November, Review section, p. 11Google ScholarPubMed

Roses, A. D. 1994. ‘Apolipoprotein affects the rate of Alzheimer's disease expression: ß-Amyloid burden is a secondary consequence dependent on APOE genotype and duration on disease’, Journal of Neuropathology and Experimental Neurology 53(5): 429–37CrossRefGoogle Scholar

Roses, A. D. 1995a. ‘Apolipoprotein E genotyping in the differential diagnosis, not prediction of Alzheimer's disease’, Annals of Neurology 38(1): 6–14CrossRefGoogle Scholar

Roses, A. D. 1995b. ‘Reply’, Annals of Neurology 38(6): 969CrossRefGoogle Scholar

Roses, A. D. 1996a. ‘Apolipoprotein E alleles as risk factors in Alzheimer's disease’, Annual Review of Medicine 47: 387–400CrossRefGoogle Scholar

Roses, A. D. 1996b. ‘Apolipoprotein E and Alzheimer's disease: a rapidly expanding field with medical and epidemiological consequences’, in (N. R. Relkin, Z. Khachaturian and S. Gandy (eds.), Apolipoprotein E Genotyping in Alzheimer's Disease: Annals of the New York Academy of Sciences, vol. 802: 50–7. New York: New York Academy of Sciences

Roses, A. D. 1996c. ‘Apolipoprotein E genotype: utility in clinical practice in Alzheimer's disease’, Journal of the American Geriatric Society 44: 1479–81CrossRefGoogle Scholar

Roses, A. D. 1997a. ‘APOE4 genotyping: in reply’, Journal of the American Geriatric Society 45(9): 1155–6CrossRefGoogle Scholar

Roses, A. D. 1997b. ‘Genetic testing for Alzheimer disease: practical and ethical issues’, Archives of Neurology 54: 1226–9CrossRefGoogle Scholar

Roses, A. D. 1997c. ‘Letter: Various views on anonymity’, Nature Medicine 3(1): 2CrossRefGoogle Scholar

Roses, A. D. 1998a. ‘A new paradigm for clinical evaluations of dementia: Alzheimer disease and apolipoprotein E genotypes’, in S. Post and P. Whitehouse (eds.), Genetic Testing for Alzheimer Disease: Ethical and Clinical Issues. Baltimore: Johns Hopkins University Press, pp. 37–64

Roses, A. D. 1998b. ‘Letter: Patent income’, Science 281, 18 September: 1805CrossRefGoogle Scholar

Roses, A. D. 2000a. ‘Pharmacogenetics and future drug development and delivery’, Lancet 355: 1358–61CrossRefGoogle Scholar

Roses, A. D. 2000b. ‘Pharmacogenetics and the practice of medicine’, Nature 405: 857–65CrossRefGoogle Scholar

Roses, A. D. 2002a. ‘Genome-based pharmacogenetics and the pharmaceutical industry’, Nature Reviews Drug Discovery 1: 541–9CrossRefGoogle Scholar

Roses, A. D. 2002b. ‘Pharmacogenetics’ place in modern medical science and practice', Life sciences 70: 1471–80CrossRefGoogle Scholar

Roses, A. D. 2002c. ‘SNPs – where's the beef?’, Pharmacogenomics Journal 2: 277–83CrossRefGoogle Scholar

Roses, A. D. and Saunders, A. M. 1996. ‘Letter: evaluation of suspected dementia’, New England Journal of Medicine 335(26): 1996Google ScholarPubMed

Roses, A. D. and Saunders, A. M. 1997. ‘Prediction for unimpaired subjects is different from diagnosis of demented patients’, Annals of Neurology 41(3): 414–15CrossRefGoogle ScholarPubMed

Roses, A. D., Strittmatter, W., Periack-Vance, M. A., Corder, E. H., Saunders, A. M. and Schmechel, D. E. 1994. ‘Letter: clinical application of apolipoprotein E genotyping to Alzheimer's disease’, Lancet, 343: 1564–5CrossRefGoogle ScholarPubMed

Ross, J. S. and Fletcher, J. A. 1998. ‘The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy’, Stem Cells 16: 413–28CrossRefGoogle ScholarPubMed

Rothenberg, M. L., Cabone, D. P. and Johnson, D. H. 2003. ‘Improving the evaluation of new cancer treatments: challenges and opportunities’, Nature Reviews Cancer 3: 303–9CrossRefGoogle ScholarPubMed

Rothman, B. K. 1998. Genetic Maps and Human Imaginations: The Limits of Science in Understanding Who We Are. New York: (W. W. Norton

Rothstein, M. A. (ed.) 2003. Pharmacogenomics: Social, Ethical and Clinical Dimensions. New York: John Wiley

Rothstein, M. and Griffin Epps, P. 2001. ‘Ethical and legal implications of pharmacogenomics’, Nature Reviews Genetics 2: 228–31CrossRefGoogle ScholarPubMed

Rothstein, M. and Hornung, C. A. 2003. ‘Public attitudes about pharmacogenomics’, in Rothstein 2003

Rusnak, J. M., Kisabeth, R. M., Herbert, D. P. and McNeil, D. M. 2001. ‘Pharmacogenomics: a clinician's primer on emerging technologies for improved patient care’, Mayo Clinic Proceedings 76: 299–309CrossRefGoogle ScholarPubMed

Sadée, W. 1999. ‘Pharmacogenomics’, British Medical Journal 319: 1286CrossRefGoogle Scholar

Sainio, C. and Lauri, S. 2003. ‘Cancer patients’ decision-making regarding treatment and nursing care', Journal of Advanced Nursing 41(3): 250–60CrossRefGoogle ScholarPubMed

Salter, B. G. 1998. The Politics of Change in the Health Service. London: Macmillan

Saunders, A. M., Strittmatter, W. J., Schmechel, D., Georgehyslop, P. H. S., Periack-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crappermaclachlan, D. R., Alberts, M. J., Hulette, C., Crain, B., Goldgaber, D. and Roses, A. D. 1993. ‘Association of apolipoprotein E allele ∊4 with late-onset familial and sporadic Alzheimer's disease’, Neurology 43: 1467–72CrossRefGoogle ScholarPubMed

Saunders, A. M., Trowers, M. K., Shimkets, R. A., Blakemore, S., Crowther, D. J., Mansfield, T. A., Wallace, D. M., Strittmatter, W. J. and Roses, A. D. 2000. ‘The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection’, Biochimica et Biophysica Acta 1502: 85–94CrossRefGoogle ScholarPubMed

Saunders, A. M., Hulette, C., Welsh-Bohmer, K. A., Schmechel, D. E., Crain, B., Burke, J. R., Alberts, M. J., Strittmatter, W. J., Breitner, J. C. S., Rosenberg, C., Scott, S. V., Gaskell, P. C., Periack-Vance, M. A. and Roses, A. D. 1996. ‘Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease’, Lancet 348: 90–3CrossRefGoogle ScholarPubMed

Schappert, K., Sevigny, P. and Poirier, J. 2002. ‘Apolipoprotein E as a marker in the treatment of Alzheimer's disease’, in B. Lerer, (ed.), Pharmacogenetics of Psychotropic Drugs. Cambridge: Cambridge University Press, pp. 360–71

Schmitz, G., Aslanidis, C. and Lackner, K. J. 2001.‘Pharmacogenomics: implications for laboratory medicine’, Clinica Chimica Acta 308: 43–53CrossRefGoogle ScholarPubMed

Schnitt, S. J. and Jacobs, T. W. 2001. ‘Current status of HER2 testing: caught between a rock and a hard place’, American Journal of Clinical Pathology 116: 806–10CrossRefGoogle Scholar

Shak, S. 1999. ‘Overview of the Trastuzumab (Herceptin) Anti-HER2 Monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer’, Seminars in Oncology 26(4), supplement 12: 71–7Google ScholarPubMed

Shapiro, S. D. 2003. ‘The post-genomic red journal charting the path from hope (not hype) to cure’, American Journal of Respiratory Cell and Molecular Biology 29(4): 425–6CrossRefGoogle Scholar

Shi, M. M., Bleavins, M. R. and Iglesia, F. 2001. ‘Pharmacogenetics application in drug development and clinical trials’, Drug Metabolism and Disposition 29(4), part 2: 591–5Google ScholarPubMed

Siest, G., Bertrand, P., Herbeth, B., Vincent-Viry, M., Schiele, F., Sass, C. and Visvikis, S. 2000. ‘Apolipoprotein E polymorphisms and concentration in chronic disease and drug responses’, Clinical Chemistry and Laboratory Medicine 38(9): 841–52CrossRefGoogle ScholarPubMed

Sinding, C. 1996. ‘Literary genres and the construction of knowledge in biology: semantic shifts and scientific change’, Social Studies of Science 26: 43–70CrossRefGoogle Scholar

Sjögren, M., Hesse, C., Basun, H., Köl, G., Thostrup, H., Kilander, L., Marcusson, J., Edman, A., Wallin, A., Karlsson, I., Troell, M., Wachtmaister, G., Ekdahl, A., Olofsson, H., Sandström, A., Andreasen, N., Minthon, L. and Blennow, K. 2001. ‘Tacrine and rate of progression in Alzheimer's disease – relation to ApoE allele genotype’, Journal of Neural Transmission 108: 451–8CrossRefGoogle ScholarPubMed

Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, A., Ullrich, A. and Press, M. F. 1987. ‘Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu Oncogene’, Science 235: 177–82CrossRefGoogle ScholarPubMed

Smith, R. 2000. ‘The failings of NICE’, British Medical Journal 321: 1363–4CrossRefGoogle ScholarPubMed

Spear, B. B., Heath-Chiozzi, M. and Huff, J. 2001. ‘Clinical applications of pharmacogenetics’, Trends in Molecular Medicine 7(5): 201–4CrossRefGoogle Scholar

Speyer, J. 2002. ‘Cardiac dysfunction in the Trastuzumab clinical experience’, Journal of Clinical Oncology 20(5): 1156–7CrossRefGoogle ScholarPubMed

Stebbing, J., Copson, E. and O'Reilly, S. (2000) ‘Herceptin (Trastuzumab) in advanced breast cancer’, Cancer Treatment Reviews 26: 287–90CrossRefGoogle Scholar

Steimer, W. and Potter, J. M. 2002. ‘Pharmacogenetic screening and therapeutic drugs’, Clinica Chimica Acta 315: 137–55CrossRefGoogle ScholarPubMed

Sugarman, J., McCrory, D. C., Powell, D., Krasny, A., Adams, B., Ball, E. and Cassell, C. 1999. ‘Empirical research on informed consent. An annotated bibliography’, Hastings Center Report 29(1): S1–42CrossRefGoogle ScholarPubMed

Summers, W. K., Majovski, L. V., Marsh, G. M., Tachiki, K. and Kling, A. 1986. ‘Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type’, New England Journal of Medicine 315(20): 1241–45CrossRefGoogle ScholarPubMed

Sun, . 2002. ‘Sun Says; Leading Article’, Sun. 16 March, p. 8Google Scholar

Sykes, R. 1999. ‘Medical innovation and imperatives’, Getting Better: Developing Mechanisms to Ensure the Best Benefit for Patients from Medical Progress, proceedings of conference, Brussels, 24 November, pp. 11–14

Taylor, K. M. 1992. ‘Integrating conflicting professional roles: physician participation in randomised clinical trials’, Social Science and Medicine 35(2): 217–24CrossRefGoogle Scholar

Taylor, P. 1996. ‘Anticholinesterase agents’, in Goodman, and Gilman's The Pharmacological Basis of Therapeutics, ed. J. G. Hardman and L. E. Limbird. 9th edn. New York: McGraw-Hill, pp. 161–76

Thomas, F. and de Ribains, G. 1998. Pharmacogenomics. London: Financial Times

Thomas, S. 2001. ‘Pharmacogenetics: the ethical context’, Pharmacogenomics Journal 1: 239–42CrossRefGoogle ScholarPubMed

Thornton, J. 2002. ‘Let this be last scandal’, Sun, 16 March, p. 29Google Scholar

Timmermans, S. and Berg, M. 2003. ‘The practice of medical technology’, Sociology of Health and Illness 25: 97–114CrossRefGoogle ScholarPubMed

Tiner, T. 2003. ‘ABPI call for NICE guidance to be made mandatory’, Lancet Oncology 4: 203–4CrossRefGoogle ScholarPubMed

Tollman, P., Guy, P., Altshuler, J., Flanagan, A. and Steiner, M. 2001. A Revolution in R&D. How Genomics and Genetics are Transforming the Biopharmaceutical Industry. Boston: Boston Consulting Group, http://www.bcg.com/publications/files/eng_genomicsgenetics_rep_11_01.pdf

Tozer, J. 2001. ‘Postcode lottery has condemned me to death; Despair of the cancer victims hit by drug “rationing”’, Daily Mail, 15 August, p. 32Google Scholar

Trojanowski, J. Q. 2002. ‘Tauists, Baptists, Syners, Apostates, and new data’, Annals of Neurology 52(3): 263–4CrossRefGoogle ScholarPubMed

Tsai, Y. J. and Hoyme, H. E. 2002. ‘Pharmacogenomics: the future of drug therapy’, Clinical Genetics 62: 257–64CrossRefGoogle ScholarPubMed

Tunstall, N. and Lovestone, S. 1999. ‘Letter: UK Alzheimer's Disease Genetics Consortium’, International Journal of Geriatric Psychiatry 14: 789–913.0.CO;2-V>CrossRefGoogle ScholarPubMed

Turney, J. 1998. ‘Signs of life – taking genetic literacy seriously’, in P. Glasner and H. Rothman (eds), Genetic Imaginations – Ethical, Legal and Social Issues in Human Genome Research. Aldershot: Ashgate, p. 131–40

Gool, W. A. 1996. ‘The use of apolipoprotein E genotyping as a diagnostic test in suspected Alzheimer's disease’, Annals of the New York Academy of Sciences 802: 79–91Google ScholarPubMed

Lente, H. and Rip, A. 1998. ‘The rise of membrane technology: from rhetorics to social reality’, Social Studies of Science 28(2): 221–54CrossRefGoogle Scholar

Varekamp, I., Krol, L. J. and Danse, J. A. C. 1998. ‘Age rationing for renal transplantation? The role of age in decisions regarding scarce life extending medical resources’, Social Science and Medicine 47(1): 113–20CrossRefGoogle ScholarPubMed

Vaszar, L. T., Cho, M. K. and Raffin, T. A. 2003. ‘Privacy issues in personalized medicine’, Pharmacogenomics 4(2): 107–12CrossRefGoogle ScholarPubMed

Vaszar, L. T., Rosen, G. D. and Raffin, T. A. 2002. ‘Pharmacogenomics and the challenge to privacy’, Pharmacogenomics Journal 2: 144–7CrossRefGoogle ScholarPubMed

Veenstra, D. L. and Higashi, M. K. 2000. ‘Assessing the cost-effectiveness of pharmacogenomics’, AAPS Pharmsci 2(3), article 29: 1–11CrossRefGoogle ScholarPubMed

Venter, C. 2000. ‘Genomic impact on pharmaceutical development’, in From Genome to Therapy: Integrating Technologies with Drug Development, Novartis Foundation Symposium 229. Chichester: John Wiley, pp. 14–18

Vesell, E. 2000. ‘Introduction’, Pharmacology 61: 118–23CrossRefGoogle ScholarPubMed

Wachbroit, R. 1998. ‘The question not asked: the challenge of pleiotropic genetic tests’, Kennedy Institute of Ethics Journal 8(2): 131–44CrossRefGoogle Scholar

Waitzkin, H. 1991. The Politics of Medical Encounters: how Patients and Doctors Deal with Social Problems. New Haven: Yale University Press

Walker, R. 2001. ‘Letter: “Spinning” is not nice’, British Medical Journal 322: 490Google Scholar

Warren, V. 1999. Genetic Tests and Future Need for Long-Term Care in the UK. http://www.phgu.org.uk/info_database/policy/cccreport.html

Watkins, P. B., Zimmerman, H. J., Knapp, M. J., Gracon, S. I. and Lewis, K. W. 1994. ‘Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease’, Journal of the American Medical Association 271: 992–8CrossRefGoogle ScholarPubMed

Weber, W. W. 2001. ‘The legacy of pharmacogenetics and potential applications’, Mutation Research 479: 1–18CrossRefGoogle ScholarPubMed

Wedlund, P. J. and Leon, J. 2001. ‘Pharmacogenomic testing: the cost factor’, Pharmacogenomics Journal 1: 171–4CrossRefGoogle ScholarPubMed

Weinshilboum, R. 2002. ‘The genomic revolution and medicine’, Mayo Clinic Proceedings 77(8): 745–6CrossRefGoogle Scholar

Weiss, R. 2000. ‘The promise of precision prescriptions; ‘pharmacogenomics’ also raises issues of race, privacy’, Washington Post, 24 June, p. A01Google Scholar

Welsh-Bohmer, K. A., Gearing, M., Saunders, A. M., Roses, A. D. and Mirra, S. 1997. ‘Apolipoprotein E genotypes in a neuropathological series from the consortium to establish a registry for Alzheimer's disease’, Annals of Neurology 42(3): 319–25CrossRefGoogle Scholar

Whitehouse, P. J. 1998. ‘Therapeutic interventions in Alzheimer's disease: implications of genetic advances’, in (S. G. Post and (P. J. Whitehouse (eds.), Genetic Testing for Alzheimer's Disease: Ethical and Clinical Issues. Baltimore: Johns Hopkins University Press, pp. 65–82

Whitehouse, P. J. and Geldmacher, D. S. 1996. ‘Reply’, New England Journal of Medicine 335(26): 1997–8Google Scholar

Wieczorek, S. J. and Tsongalis, G. J. 2001. ‘Pharmacogenomics: will it change the field of medicine?’, Clinica Chimica Acta 308: 1–8CrossRefGoogle Scholar

Wilcock, G. K., Lilienfeld, S. and Gaens, E. on behalf of the Galantamine International-1 Study Group. 2000. ‘Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial’, British Medical Journal, 9 December, 321: 1–7CrossRefGoogle ScholarPubMed

Wilcock, G. K., MacGowan, S. H., Scott, M. and Dawbarn, D. 1995. ‘Apolipoprotein E genotype and response to tacrine in Alzheimer's disease’, poster presented at the International Psychogeriatrics Association Conference, Apolipoprotein E et Maladie d'Alzheimer, 29 May, Paris

Wiley, S. R. 1998. ‘Genomics in the real world’, Current Pharmaceutical Design 4: 417–22Google ScholarPubMed

Williams, C. J. and Buchanan, R. B. 1987. The Medical Management of Breast Cancer. Tunbridge Wells: Castle House

Winblad, B., Engedal, K., Soininen, H., Verhey, F., Waldemar, G., Wimo, A., Wetterholm, A. L., Zhang, R., Haglund, A. and Subbiah, P. 2001. ‘A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD’, Neurology 57: 489–95CrossRefGoogle ScholarPubMed

Wiseman, H. 1994. Tamoxifen: Molecular Basis of Use in Cancer Treatment and Prevention. Chichester: John Wiley

Wolf, C. R., Smith, G. and Smith, R. L. 2000. ‘Pharmacogenetics’, British Medical Journal 320: 987–90CrossRefGoogle ScholarPubMed

Woodman, R. 2000. ‘Storage of human organs prompts three inquiries’, British Medical Journal 320 (8 January): 77CrossRefGoogle ScholarPubMed

Workman, P. 2001a. ‘Changing times: developing cancer in genomeland’, Current Opinion in Investigational drugs 2(8): 1128–35Google Scholar

Workman, P. 2001b. ‘Scoring a bull's-eye against cancer genome targets’, Current Opinion in Pharmacology 1: 342–52CrossRefGoogle Scholar

World Medical Association 2000. Declaration of Helsinki. Geneva: World Medical Association

Yaziji, H. and Gown, A. M. 2002. ‘Testing for HER-2/neu in breast cancer: is fluorescence in situ hyridization superior in predicting outcome?’, Advances in Anatomic Pathology 9(6): 338–44CrossRefGoogle Scholar

Young, R. and Surrusco, M. 2001. Rx R&D Myths: the Case Against the Drug Industry's R&D ‘Scare Card’. Washington, DC: Public Citizen Congress Watch

Yu, D. and Hung, M. 2000. ‘Role of erbB2 in breast cancer chemosensitivity’, BioEssays 22: 673–803.0.CO;2-A>CrossRefGoogle ScholarPubMed

Zussman, R. 1992. Intensive Care: Medical Ethics and the Medical Profession. Chicago: University of Chicago Press

Zussman, R. 1997. ‘Sociological perspectives on medical ethics and decision-making’, Annual Review of Sociology 23: 171–89CrossRefGoogle Scholar

Abate, T. 2001a. ‘Genentech can widen drug's use’, San Francisco Chronicle, 15 May, p. B1Google Scholar

Abate, T. 2001b. ‘Researchers ready to move to next genome discoveries; drug developers to see new tools at Trade Show’, San Francisco Chronicle, 5 March, p. C1Google Scholar

Abraham, J. 1995. Science, Politics and the Pharmaceutical Industry: Controversy and Bias in Drug Regulation. London: University College London/St Martins Press

Aerssens, J. 2002. ‘Pharmacogenomic approaches in Alzheimer's disease drug development’, Drug Development Research 56: 67–73CrossRefGoogle Scholar

AGS Ethics Committee 2001. ‘Genetic testing for late-onset Alzheimer's disease’, Journal of the American Geriatric Society 49: 225–6CrossRef